Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29278897 | 1.00 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL2024939 | 0.93 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL2028811 | 0.93 | PIK3CG (0.55) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL29314052 | 0.87 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL30019484 | 0.86 | PIK3CG (0.47) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL25865345 | 0.86 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL21929763 | 0.85 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22768493 | 0.85 | PIK3CG (0.48) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL22440915 | 0.85 | PIK3CG (0.54) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB | |
| SCHEMBL31461112 | 0.85 | PIK3CG (0.48) | PIK3CGPIK3CDPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638687-A | Aromatic heterocyclic pyrrolidones and uses thereof | 杭州百新生物医药科技有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240226104-A1 | PI3K INHIBITORS, NANOFORMULATIONS, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-11 | — | — | US | disclosed |
| US-20240226104-A1 | PI3K INHIBITORS, NANOFORMULATIONS, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-11 | — | — | US | disclosed |
| US-20240226104-A1 | PI3K INHIBITORS, NANOFORMULATIONS, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-11 | — | — | US | disclosed |
| CN-117545479-A | PI3K inhibitor, nano preparation and application thereof | 密歇根大学董事会 | 2024-02-09 | — | — | CN | disclosed |
| WO-2020247496-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226104-A1 | PI3K INHIBITORS, NANOFORMULATIONS, AND USES THEREOF | PI4KA, PIK3CA, PI4KB | PIK3CG 4/4885PIK3CD 5/4885PIK3R1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.